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ABSTRACT
Background and objective There is an urgent need 
for robust data on the trajectories and outcomes of 
pregnancies in women with inflammatory rheumatic 
diseases (IRD). In particular when rare outcomes or rare 
diseases are to be investigated, collaborative approaches 
are required. However, joint data analyses are often 
limited by the heterogeneity of the different data sources.
To facilitate future research collaboration, a European 
League Against Rheumatism (EULAR) Task Force defined 
a core data set with a minimum of items to be collected 
by pregnancy registries in rheumatology covering the 
period of pregnancy and the 28- day neonatal phase in 
women with any underlying IRD.
Methods A stepwise process included a two- round 
Delphi survey and a face- to- face meeting to achieve 
consensus about relevant items.
Results A total of 64 multidisciplinary stakeholders 
from 14 different countries participated in the two 
rounds of the Delphi process. During the following 
face- to- face meeting of the EULAR Task Force, consensus 
was reached on 51 main items covering ’maternal 
information’, ’pregnancy’ and ’treatment’. Generic 
instruments for assessment are recommended for 
every item. Furthermore, for the five most frequent 
IRDs rheumatoid arthritis, spondyloarthritis, juvenile 
idiopathic arthritis, systemic lupus erythematosus 
and other connective tissue diseases, disease- specific 
laboratory markers and disease activity measurements 
are proposed.
Conclusion This is the first consensus- based core data 
set for prospective pregnancy registries in rheumatology. 
Its purpose is to stimulate and facilitate multinational 
collaborations that aim to increase the knowledge about 
pregnancy course and safety of treatment in women with 
IRDs during pregnancy.
INTRODUCTION
In recent years, several European pregnancy regis-
tries have been established in rheumatology to 
prospectively collect and analyse data on pregnant 
women with different inflammatory rheumatic 
diseases (IRD). However, certain research issues, 
for example, studying the pregnancy course in rare 
diseases, require even larger study populations, 
often exceeding the number of patients available 
in each registry, making collaborative analyses 
desirable. The European League Against Rheuma-
tism (EULAR) Task Force on antirheumatic drugs 
during pregnancy and lactation1 also highlighted 
the need for collaboration to collate data on newer 
medications.
Combined analysis of data from different sources 
requires a certain degree of homogeneity among the 
data collected. A recent comprehensive survey of four 
registries working together in the European Network 
of Pregnancy Registries in Rheumatology (EuNeP) 
showed similar study designs in terms of prospective 
data collection, inclusion of patients with IRD before 
or during early pregnancy, and reporting of data in 
each trimester of pregnancy.2 However, major differ-
ences were found in the details of data collection, for 
example, in the instruments used to measure disease 
activity. As highlighted by other initiatives in rheu-
matology, harmonising and standardising items and 
their measurement across studies is critical to facili-
tate collaborative research.3–6
A EULAR Task Force was therefore convened 
to define a core data set for registries and obser-
vational studies that prospectively collect informa-
tion about pregnant women with IRD including 
the neonatal phase (four weeks post partum). The 
core set was developed to encompass a minimum of 
standardised items to be collected paving the way 
for multinational collaborations.
METHODS
An iterative process according to EULAR stan-
dardised operating procedures was applied to 
develop the core set.7 The Task Force comprised 
a convenor (AS) and coconvenor (RFB), a meth-
odologist (AZi), a fellow (YM), eight Task Force 
members (LA, NC- C, RJEMD, FF, AM, CN- P, LR, 
MW), three EMEUNET members (DDC, SCRG, 
SS), two patient research partners (DG, RÖ) and 
one health professional (AZb). The scope and core 
areas of the core set according to the Core Outcome 
Set- STAndards for Development recommendations 
were defined by consensus.8 A study protocol was 
developed and circulated among the Task Force. 
The flow chart gives an overview of all steps taken 
during the project (figure 1).
Generation of items
Items estimated relevant to be included in the core 
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search (see online supplemental for details) and underpinned (2) 
by an inventory of items collected by registries participating in 
EuNeP2 and (3) from results of a survey among three EuNeP 
patient representatives regarding their needs during preg-
nancy. An initial list of items was created by deleting duplicates, 
grouping similar items and refinement. Consequently, every item 
on the list was assigned to its respective core area.
Consensus process, outcome scoring and consensus definition
The importance of each item for the final core set was judged by 
a stepwise consensus process encompassing a two- round Delphi 
survey and a final vote. In addition to the members of the EULAR 
Task Force (except the fellow), additional experts in the field of 
pregnancy and rheumatology from different European countries 
were invited to participate during the Delphi votes. In partic-
ular, up to five clinicians involved in each of the four registries 
of the EuNeP collaboration, as well as clinical researchers and 
experts in the areas of rheumatology, epidemiology, obstetrics, 
gynaecology, internal medicine as well as other health profes-
sionals were directly invited by email. The Delphi process was 
performed using the online tool ‘Delphi Manager’ (http://www. 
comet- initiative. org/ delphimanager/). This tool ensures the 
anonymity of all participants and adherence to the single steps 
of the Delphi process.
Participants were asked to rate the importance of each item to 
be included in a core set for pregnancy registries in rheumatology 
using the Grading of Recommendations, Assessment, Develop-
ment and Evaluations scale9 from 1 to 9 (1–3=not important, 
4–6=important but not critical, 7–9=critical/very important). 
The participants had the option to indicate an item as ‘unable 
to score’ if necessary and could give comments on each item. 
Additionally, adding comments at the end of the survey was 
also possible. The scores of every participant were anonymous 
throughout the survey. Finally, participants were asked to suggest 
additional items that were not listed in the initial item list. All 
suggested, additional items were thoroughly reviewed by nine 
Figure 1 Flow chart of the development and consensus process for the core data set. EULAR, European League Against Rheumatism; EuNeP, 
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members of the Task Force, and eligible items were added in 
Delphi round 2.
Every participant of Delphi round 1 was invited to rescore the 
items in round 2 taking total scoring results (given as percent-
ages of all participants scoring 1–9) and their own scores of 
round 1 into account. Each Delphi round had to be completed 
within 3 weeks. After completion of both Delphi rounds, scores 
of round 2 were summarised and assigned to one of the three 
pre- specified consensus definitions comprising ‘consensus in’, 
‘consensus out’ and ‘equivocal’ (table 1) according to OMERACT 
recommendations.10
All items that neither reached ‘consensus in’ nor ‘consensus 
out’ were defined as equivocal and needed a final voting. The 
final voting took place at a face- to- face consensus meeting of 
the EULAR Task Force. During this meeting the items were 
discussed and finally voted on. The voting was conducted via a 
mobile phone based electronic voting system ( www. tedme. com). 
Items that reached a majority of votes were included into the 
core set, those with a majority of negative votes were excluded. 
Furthermore, the Task Force refined the core set and discussed 
all items with ‘consensus- in’ status regarding their applicability 
in a core set and usefulness for research purposes. Of note, the 
way of assessment of each item and their exact definition was 
not subject of the Delphi voting.
Since the core set is supposed to cover items important 
for a variety of IRDs, it was strengthened during the Task 
Force meeting to also define additional, disease- specific items 
covering laboratory markers as well as disease activity and 
damage measurements. All relevant items were summarised by 
the Task Force and the importance of each item for the respec-
tive disease was rated in a written non- anonymous voting. Each 
Task Force member made her/his decisions according to her/his 
expertise in the field. Items that reached a majority of positive 
votes were included in the additional item list. The additional 
items were defined for the most prevalent IRDs in women 
of reproductive age: rheumatoid arthritis, spondyloarthritis, 
juvenile idiopathic arthritis, systemic lupus erythematosus 
and other connective tissue diseases. Other connective tissue 
diseases include Sjögren’s syndrome, undifferentiated connec-
tive tissue disease, scleroderma, myositis and mixed connective 
tissue diseases.
Data analysis
For both Delphi rounds, mean and SD, median, minimum and 
maximum as well as the distribution of scores within the three 
consensus categories were calculated using SAS software V.9.4.
RESULTS
Stakeholders
In total, 73 experts received an email invitation to participate 
in the Delphi vote, including 17 members of the EULAR Task 
Force. Of all experts invited, 65 (89%) participated in round 1 
and 64 (88%) in round 2. About two- thirds of the experts (69%) 
participating in both Delphi rounds were women. The majority 
of participants (81%) had 10 years or more work experience, 
14% were working for at least 5 and up to 10 years, and 5% 
indicated 5 years or less work experience. A total of 84% were 
rheumatologists, 5% each were obstetricians and epidemiolo-
gists, 3% each patients and midwives. Experts from 14 different 
European countries were represented (online supplemental table 
1 shows country distribution).
Definition of core areas
Three core areas were defined as ‘maternal information’, 
‘pregnancy’ and ‘treatment’ (figure 2). ‘Maternal information’ 
includes the core domains demographics and risk behaviours, 
disease characteristics of the underlying IRD and prevalent 
comorbidities. The core area ‘pregnancy’ encompasses informa-
tion on obstetrical history, the course, outcomes and delivery of 
the current pregnancy and outcomes of the neonate. In the core 
area ‘treatment’, medical treatment within 12 months prior to 
conception, the treatment of the IRD during pregnancy and post 
partum as well as the use of other treatments during pregnancy 
are subsumed.
Results of the consensus process for non-disease specific 
items
A total of 143 items were up for voting in Delphi round 1. Of 
those, 77 items were voted as critically important by at least 
70% of the participants. Another 69 new items were suggested 
to be added to the following Delphi round. All of them were 
thoroughly reviewed by eight members of the Task Force, and 
five items were considered as new and relevant for the item list 
(online supplemental table 2). They encompass gestational age at 
birth in previous pregnancies, number of previous miscarriages, 
neonatal infections, the use of non- steroidal anti- inflammatory 
drugs (NSAIDs) and start and stop dates of NSAID treatment.
With the newly suggested items of round 1, Delphi round 
2 included a total of 148 items. Of those, 89 items reached 
consensus in during the vote, none of the items reached consensus 
out and 59 items were rated as equivocal and were therefore 
neither in nor excluded (figure 1, online supplemental table 3).
At a face to face meeting of the Task Force members (n=12), 
all equivocal items were voted on. Task Force members who 
were unable to attend the meeting (n=5) received the voting 
list in advance and their votes were incorporated into the deci-
sion process. Additionally, participants of the meeting discussed 
and evaluated all items of the final core set with respect to the 
importance of the item for research purposes and redundancy. 
All decisions are explained in detail in online supplemental table 
3. In order to make the extensive list of the resulting 78 included 
items more comprehensible for the user, the items were conse-
quently defined as either main item (n=51) or operationalizing 
item (n=27). Items of the final core set are presented in table 2. 
Furthermore, the way of assessment/operationalisation for each 
Table 1 Consensus definitions
Decision Definition Explanation
Delphi round 1/2
  Consensus in ≥70% of the participants 
rated the item as critically 
important for the core data 
set (scores 7–9)
Item will be included into the 
final core data set
  Consensus out ≥70% of the participants 
rated the item as not 
important for the core data 
set (scores 1–3)
Item will be excluded from 
the final core data set
  Equivocal All items that are neither 
in the consensus- in nor in 
the consensus- out group
No consensus was reached 
for the respective item. Final 
decision at the consensus 
meeting
Face- to- face consensus meeting
  Consensus in Simple majority (>50% 
of votes)
Item will be included into the 
final core data set
  Consensus out Simple majority (>50% 
of votes)
Item will be excluded from 
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main item including instruments and categories where appro-
priate was defined and summarised in the online supplemental 
table 4.
Recommendations for disease-specific items
The recommended laboratory markers and disease activity 
measurements found to be relevant by the Task Force for the five 
IRDs rheumatoid arthritis, spondyloarthritis, juvenile idiopathic 
arthritis, systemic lupus erythematosus and other connective 
tissue diseases are presented in table 3. It is recommended for 
registers to collect the single components of a summary score 
rather than only the score, for example, C reactive protein 
(CRP), 28 swollen and tender joint count (SJC, TJC) rather than 
collecting only the disease activity score Disease Activity Score 
based on 28 tender and swollen joints and C reactive protein.
Methodological considerations
Pregnancy registries are prospective observational cohort studies 
that collect essential clinical information related to pregnancy 
in order to improve the safety of mother and child. The items 
defined with this core set refer to women with IRD and cover 
the pregnancy and the neonatal phase. The Task Force recom-
mends that patients should be enrolled at the earliest possible 
point in time during pregnancy. Data should ideally be collected 
once every trimester and during the neonatal phase (within 
28 days after birth). Besides the collection of items and their 
operationalisation, the visit date of every documented encounter 
between patient and physician should be reported. In addition, 
each registry must define, prior to its start, those diagnoses that 
shall be covered by the study.
DISCUSSION
We present the first consensus- based core data set for pregnancy 
registries in rheumatology. The comprehensive list of 51 main 
items should be uniformly collected by all pregnancy registries in 
rheumatology to ensure homogeneity and comparability of data 
and to enable joint utilisation of different data sources.
To date, no such recommendations for pregnancy registries 
in rheumatology are available even though the need has been 
highlighted previously.1 11 In the absence of common stan-
dards, published pregnancy studies in rheumatology are highly 
heterogeneous, leading to partly controversial results12 or non- 
comparable information.13 In 2008, Schaefer et al summarised 
the objectives of pregnancy studies based on data of Teratology 
Information Services (TIS) and explained how they document and 
evaluate drug effects on pregnancy.14 Although most of the vari-
ables are also essential for pregnancy registries in rheumatology, 
TIS are not tailored to patients with IRD. Since the chronic 
disease itself can affect the pregnancy and its outcomes,15 it is 
essential to collect specific information on the disease course of 
IRD by registries and observational cohorts.
Recently, Vinet et al compiled basic lists with variables to 
be collected by rheumatic pregnancy registries focusing on the 
most important information needed to answer questions about 
disease activity, medication use and pregnancy outcome.16 Many 
variables correspond to the herein proposed core set. However, 
this core set goes beyond the list of desirable information and 
makes recommendations on how and in what way the informa-
tion should be collected in order to harmonise different data 
sources. In addition, the Task Force has summarised disease- 
specific parameters that are essential for assessing the course and 
severity of the IRD. Further differences can be found in meth-
odological aspects. Vinet and colleagues followed an individual 
approach representing their (North American) views, while the 
core set is based on a structured consensus process following the 
methodology for EULAR recommendations. A variety of Euro-
pean experts in the field as well as patient representatives were 
involved. Registry holders and users were able to incorporate 
their experience into the different steps of the voting process, 
and the Task Force has taken the feasibility of implementing the 
core set in everyday clinical practice in different countries into 
account. International acceptance therefore can be expected to 
be high.
This EULAR endorsed core set represents clinically relevant 
and feasible parameters that are critical for scientific research, 
especially with a focus on multinational collaborations. The 
challenge of the stepwise consensus process was to select the 
most relevant items regarding maternal information and the 
rheumatic disease as well as pregnancy and neonatal outcomes. 
This explains the inclusion of 51 items, which is—in comparison 
to other core sets in rheumatology3–5 or core sets with relation to 
maternal and new- born’s health17—quite an extensive list.
The core set is a compromise between scientific purposes and 
research interests on the one hand and the feasibility for rheu-
matologists and other physicians or study nurses that document 
data from daily care on the other hand. We are for example 
aware of the importance of recording intrauterine growth 
restriction (IUGR) to differentiate between infants born small 
for gestational age (SGA) into those with a steady foetal devel-
opment in rather lower percentiles of the growth curves versus 
those foetuses that first develop normally and then experience a 
sudden growth disturbance. However, we presume that informa-
tion on IUGR may either be not available for many pregnancies 
or—since IUGR and SGA are often used interchangeably—their 
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Table 2 Main items of the final core data set for pregnancy 






Demographics and risk behaviours
1   Age Date of birth or month/year of birth
2   Height cm
3   Weight before (or in 
early) pregnancy
kg
4   Educational level Highest educational level according 
to national standards or/total years of 
completed education
5   Alcohol consumption 
during pregnancy
Categorisation: yes/no




7   IRD diagnosis Physician reported clinical diagnosis*
8   Classification criteria Indication, which criteria are fulfilled
9   Disease duration Month/year or year of diagnosis
10   Physician reported IRD 
severity
NRS or VAS
11   Auto- antibodies† See additional recommendations 
(table 3)
12   Physician reported flares Assessment of (1) yes/no; (2) number 
of flares
13   Physician reported 
disease activity
NRS or VAS
14   Disease activity by score† See additional recommendations 
(table 3)
15   C reactive protein eg, mg/L
16   Patient reported disease 
activity
NRS or VAS




18   Selected prevalent 
comorbidities
Yes/no assessment of: (1) 
antiphospholipid syndrome, (2) diabetes 
mellitus, (3) arterial hypertension, 




19   Gravidity Number
20   Parity Number
21   Outcome of previous 
pregnancy(ies)
Categorised into foetal death (including 
pregnancy loss and stillbirths)/live birth; 
assessment of (1) number of foetal 
deaths and live births; (2) gestational 
age
22   Preterm birth(s) Number
23   Neonatal death(s) Number
24   Congenital 
malformations
Free text
25   Hypertensive pregnancy 
disorders
Yes/no assessment of: pre- eclampsia, 
eclampsia, HELLP syndrome
Course of current pregnancy
26   Planned pregnancy Yes/No
27   Assisted reproduction Yes/No







29   Singleton/*-/multiple 
pregnancy
Number of foetuses
30   Adverse events of 
interest
(1) Yes/no assessment of non- 
serious and serious events of: 
(a) gestational hypertension, (b) 
pre- eclampsia, eclampsia, HELLP 
syndrome, (c) gestational diabetes, (d) 
thromboembolic events; (2) date of the 
beginning of the event; (3) indication 
if the event has led to hospitalisation 
or death‡
31   Other serious adverse 
events
Assessment of (1) the kind of event as 
free text; (2) date of the beginning of 
the event; (3) indication if the event has 
led to hospitalisation or death‡
Delivery/outcome of the current pregnancy
32   Elective termination Assessment of (1) yes/no; (2) 
gestational age; (3) reasons for 
termination categorised into (a) 
termination due to malformation, (b) 
termination due to other reasons
33   Foetal death Including pregnancy loss and stillbirths; 
assessment of (1) yes/no; (2) gestational 
age (weeks) at diagnosis
34   Live birth Yes/No
35   Gestational age at 
delivery
In weeks and days
36   Preterm premature 
rupture of membranes
Yes/No
37   Mode of delivery (1) Categorised into spontaneous 
vaginal delivery/operative vaginal 
delivery/caesarean section (CS)/mode 
of delivery not specified, and in case of 
CS (2) reasons categorised into: elective 
CS/foetal reasons/maternal reasons/
combined foetal and maternal reasons/
unknown reasons
Neonatal outcomes
38   Birth weight In kilogram with two decimal digits 
or gram
39   Gender Categorisation: female/male/other
40   Breast feeding Categorisation: yes, for at least 4 weeks 
after birth/no
41   Congenital heart block Yes/No
42   Congenital 
malformations
Free text
43   Neonatal serious adverse 
events during the first 
28 days of live
Assessment of (1) the kind of event as 
free text; (2) date of the beginning of 
the event; (3) indication if the event has 
led to hospitalisation or death‡
Treatment
Treatment 12 months prior to conception
44   DMARD use Assessment of (I) yes/no; (2) name§; (3) 
start/stop dates
45   Oral glucocorticoid use Yes/No
46   Use of potentially 
teratogenic medication
Free text
IRD treatment during pregnancy and post partum
47   DMARD use Assessment of (1) yes/no; (2) name§; 
(3) dose; (4) application intervals; 
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different meaning may not always be clear. We therefore decided 
to exclude IUGR from the core set.
The supplemental material contains descriptions and defini-
tions for all main items as far as this is possible. Even though 
it would be desirable to have uniform definitions for all items, 
this is not feasible for various reasons. Registries can only collect 
data within the framework of the health system and regulatory 
requirements of their country of origin and therefore, country- 
specific differences cannot be avoided.18 19 For a number of 
items, the reporting health professional has to rely on informa-
tion that is provided by obstetricians, for example, the event of 
pre- eclampsia. Definition and classification systems however 
vary and can result in discrepancies of incidence rates.20 21
The period we were focused on for these recommendations 
was the time of pregnancy and the 28- day postpartum period 
(neonatal phase). The targeted patient population are patients 
with IRD. Since these recommendations shall be applicable to 
all IRDs, the final core set encompasses non- disease specific, 
generic items. Furthermore, for the five most prevalent IRDs, 
important laboratory markers and instruments to measure 
disease activity and damage have been defined. Of note, the core 
data set encompasses only the minimum items that have been 
classified as essential by experts in the field. It is up to each indi-
vidual registry to add further items, to ask more details for an 
item and/or to use additional instruments or categories beyond 
those that are proposed within this core set.
Our proposed core set is on one side intended to serve as 
a basis for evolving registries to prioritise and facilitate data 
collection. On the other side, the core set can be used by existing 
observational studies and registries to focus their data quality 
management on those outcomes that were found to be of high 
importance to facilitate collaborative analyses with other regis-
tries. This will enable the growing number of (pregnancy) regis-
tries in Europe to perform joint analyses, allowing to explore 
relevant aspects in more detail and with robust data.
Collecting data in different countries by applying an interna-
tionally standardised protocol offers the chance to create the 
world’s largest source of information of pregnancies in women 
with IRD including drug safety. Encouraging and recruiting 
pregnant patients and collecting reliable data is the basis to fill 
current knowledge gaps and to guide IRD patients with the wish 
to have children in the future. Such a database can also serve as 




48   Oral glucocorticoid use Assessment of (1) yes/no; (2) dose; (3) 
application intervals; (4) start/stop dates
49   Intraarticular 
glucocorticoid use
Assessment of (1) yes/no; (2) date of 
application
50   NSAID use Assessment of (1) yes/no; (2) name; (3) 
start/stop dates
Use of other treatments during pregnancy
51   Use of selected 
treatments
Yes/no assessment of use of (1) 
antihypertensive drugs, (2) aspirin, 
(3) folic acid and (4) heparin/other 
anticoagulants
Explanations of the main items are given in online supplemental table 4.
*Which diagnoses are covered by the registry, must defined in advance by every 
registry.
†Variables differ according to IRD diagnosis and are further defined in table 3.
‡This recommendation is based on the ICH E2A guideline.25
§For biological or targeted synthetic disease modifying antirheumatic drugs it is 
recommended to record the trade name.
DMARD, disease modifying anti- rheumatic drug; HELLP, complication of pregnancy 
characterised by haemolysis, elevated liver enzymes and a low platelet count; IRD, 
inflammatory rheumatic disease; NRS, Numeric Rating Scale; NSAID, non- steroidal 
anti- inflammatory drug; VAS, Visual Analogue Scale.
Table 2 Continued




Rheumatoid arthritis  ► Anti- citrullinated protein antibody (ACPA)
 ► Rheumatoid factor (RF)
 ► 28 SJC
 ► 28 TJC
 ► DAS28- CRP3
Spondyloarthritis  ► HLA- B27  ► ASDAS
 ► BASDAI
Juvenile idiopathic arthritis  ► Anti- citrullinated protein antibody (ACPA)
 ► Rheumatoid factor (RF)
 ► Antinuclear antibodies (ANA)
 ► 28 SJC
 ► 28 TJC
 ► DAS28- CRP3
Systemic lupus erythematosus  ► Antiphospholipid antibodies (aPL), in particular: anti- cardiolipin (aCL) antibodies, 
anti- beta-2- glycoprotein- I- antibodies, lupus anticoagulant (LA)
 ► Antinuclear antibodies (ANA)
 ► Anti- double- stranded DNA antibodies
 ► Extractable nuclear antigen (ENA) antibodies, in particular: anti- La/SSB 
antibodies, anti- Ro/SSA antibodies, anti- Sm antibodies, anti- U1- ribonucleoprotein 
(RNP) antibodies
 ► Serum C3/C4
 ► SLEPDAI (SLEDAI*)
 ► SLICC/ACR 
damage index
Other connective tissue diseases  ► Antiphospholipid antibodies (aPL), in particular: anti- cardiolipin (aCL) antibodies, 
anti- beta-2- glycoprotein- I- antibodies, lupus anticoagulant (LA)
 ► Extractable nuclear antigen (ENA) antibodies, in particular: anti- La/SSB 
antibodies, anti- Ro/SSA antibodies, anti- U1- ribonucleoprotein (RNP) antibodies
 ► Antinuclear antibodies (ANA)
 ► Serum C3/C4
*SLEDAI instead of SLEPDAI for postpartum disease activity.
ASDAS, Ankylosing Spondylitis Disease Activity Score; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; DAS28- CRP3, Disease Activity Score based on 28 tender and 
swollen joints and C reactive protein; SLICC/ACR Damage Index, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; SJC, 
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to establish research guidelines. With this core set, we hope to 
encourage other scientist to set up pregnancy registries and to 
collaborate in joint projects.
Strengths and limitations
The methodological strength of developing this core set is the 
application of robust methods with a stepwise consensus- based 
process7 8 22 23 involving multi- stakeholder groups, for example, 
experienced rheumatologists, epidemiologists, obstetricians, 
healthcare professionals and patients. The Delphi process is 
an established method for achieving consensus24 and has the 
advantage of maintaining the anonymity of participants. We 
had a low attrition rate with only one participant who did not 
complete both rounds. In all consensus steps, the participants 
were reminded that only those items that are both essentially 
important for joint research and feasible in daily clinical care, 
should be selected.
This core data set focuses on data collection during pregnancy 
including the outcome of pregnancy. This decision was made in 
order to achieve a minimal data set for the most important time 
period. However, information about the time before pregnancy 
and further observation of women and children after delivery 
is highly desirable in order to answer research questions like, 
for example, the time to pregnancy, early abortion/miscarriage 
rates or the development of the child beyond 4 weeks of age. 
We therefore recommend to extend the observation of the child 
beyond the time frame addressed here in order to assess long- 
term outcomes concerning child development. This is a gap in 
the current literature and should be the focus of future collabo-
rative studies with paediatricians.
CONCLUSION
This EULAR Task Force proposes a core data set with a minimum 
of items to be collected by pregnancy registries in rheumatology. 
Our aim was to facilitate collaborative research and joint data 
analyses. As the design of registries may vary considerably 
between countries and will be influenced by the different health-
care systems, this common data set was deliberately kept short 
and simple, concentrating on the most important information 
that is needed for meaningful joint analyses. We hope that this 
proposal will be useful when establishing new registries and 
also increase the willingness of rheumatologists, other health-
care professionals and patients to contribute to the registries and 
provide the necessary data.
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